Please assess the completion status of the following clinical trial:

Trial Title: Comparison the Postoperative Quality of Recovery Between Neostigmine and Sugammadex in Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia -Randomized Controlled Trial-

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients aged over 60 years who are scheduled for trans pars plana vitrectomy with general anesthesia~Exclusion Criteria:~* Neuromuscular disease~* History of malignant hyperthermia~* Significant renal or hepatic dysfunction~* Allergy to sugammadex or rocuronium~* BMI \> 30kg/m2~* History of medication which affect neuromuscular blocker such as anti-convulsants, magnesium

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex group (Type: EXPERIMENTAL): After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
- Neostigmine group (Type: ACTIVE_COMPARATOR): After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.

Based on this trial design, predict the completion outcome and termination type (if applicable).